Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

•Bevacizumab was associated with an improved median overall survival (OS) of 1.8 months.•For females, median OS benefit from bevacizumab was <1 month.•For females under the age of 60, there was no OS benefit.•Sex- and age-specific reporting is essential in future trials testing bevacizumab.